Digital digestive health company Vivante Health has concluded a $31 million Series B funding round to advance its gut health platform GIThrive. The digital platform provides virtual gastrointestinal care, linking patients with a team of physicians, dietitians and health coaches.
According to Vivante, around 70 million Americans suffer from a chronic digestive condition – twice as many as diabetes. GIThrive supports users across a range of conditions, from common ailments like IBS and GERD to more complex disorders like inflammatory bowel disease.
Alongside features like food and symptom tracking and online educational resources, GIThrive users receive AI-driven personalized care plans based on their symptoms. They also have access to a nationwide network of internists and gastroenterologists for diagnosis, treatment, lab tests and prescriptions.
Vivante says the new funding will be used to enhance GIThrive’s ability to predict the onset and progression of GI conditions. It will also support the expansion of the company’s support teams, aiding new employers, health plans and channel partners seeking effective solutions to mitigate the personal and financial impact of digestive diseases.
“One in four Americans suffers from a digestive disorder or undiagnosed digestive symptoms that affect their quality of life as well as their healthcare costs,” said Bill Snyder, CEO of Vivante. “We have proven that our scalable technology platform paired with our comprehensive care team results in better health, lower costs, and a much better experience for the members we serve.”
Vivant claims that more than 90% of GIThrive users report relief from digestive symptoms and improved quality of life. The company also says that employers adopting GIThrive have seen reductions of 15% or more in digestive-related healthcare expenditures, attributed to increased medication adherence and behavioral modifications that reduce hospital visits.
This round was led by Mercato Partners, a new investor, and featured participation from Health Catalyst Capital, along with existing investors, and brings the total capital raised by the company to $47 million.
“Vivante is reinventing the management of chronic gut conditions through its ‘right care at the right time’ triage methodology,” said Joe Kaiser of Mercato Partners. “This approach to patient-centric, digital GI management bridges the gap that exists between generalist and specialist care, giving patients back time, money, and quality of life lost to gastrointestinal issues as well as delivering a compelling ROI to employers.”
